Calico Biosystems Component
Calico Biosystems | Value Proposition

Empowering the Oncology Ecosystem

[PHARMA] [BIOTECH INNOVATORS] [CROs] [AI PLATFORMS]

The Biological Validation Your Pipeline Demands.

Intact Tumor Explant

Calico Biosystems’ ex vivo tumor explant platform provides the real-world, patient-native biological insights needed to turn multi-omic data into clinical success.

CaliTarget

Precision Target Assessment for Smarter Clinical Trials

  • Generate real‑world evidence of target expression and co‑expression across the full tumor ecosystem

  • Quantify target expression levels and the percentage of expressing cells, enabling anticipation of on‑target/off‑tumor drug effects

  • Enable rapid, cost‑effective, and accurate measurement of intact, surface‑accessible target epitopes across all cell populations, reflecting true drug accessibility

  • Integrate tumor cell lines used in prior in vitro pharmacology studies, enabling direct comparative analyses and ensuring continuity across experimental datasets

  • Incorporate mouse tumor models for cross‑species comparison, supporting the selection of in vivo models that recapitulate clinically relevant target expression levels and provide a strong, data‑driven rationale for model selection

CaliPower
Calipower Predict Anti-Cancer Drug Efficacy with Confidence

Predicts patient response at the preclinical stage with unmatched precision

ORR vs CaliPower

  • Integrate experimental multi‑omics data generated on tumors to feed proprietary algorithms that predict and quantify drug efficacy

  • Assess the efficacy of any class of oncology drugs across the top 12 solid tumor indications

  • Evaluate drug efficacy across up to six treatment conditions per tumor

  • Validated in 9 real‑world studies comparing CaliPower drug efficacy scores with clinical objective response rates (ORR)

  • Validated across 7+ indications and >300 patient tumor specimens

  • Enable ranking of lead drug candidates and benchmarking against standard of care (SoC) and competitor therapies

  • Support indication prioritization and optimal combination selection for clinical development

  • Anticipate dose efficacy and inform dose–response relationship studies

CaliHow

Decipher the mechanism of action of your drug to enhance therapeutic potency

  • Leverage multi‑omics data generated from tumor exposure to drugs to characterize MoA in situ at cellular and molecular levels

  • Rationally design and evaluate drug combinations to enhance clinical potency

  • Identify and validate experimental biomarkers of drug responsiveness

  • Enable patient stratification strategies and the design of clinical cohorts enriched for responders

  • Build a precision medicine framework to maximize therapeutic impact and durability of response

Calitarget
CALIDATA

 

Starting 2027

Access a unique, large-scale patient tumor data library ubnder on- and off-treatment conditions

CaliData

  • CaliData captures tumor responses across multiple controlled drug perturbations, creating a distinctive dataset

  • Deep multi‑omics profiles linked to clinical and pathological annotations at the patient level

  • A proprietary, dynamic data asset that trains AI models, guides drug design, and predicts clinical outcomes with high accuracy

Book an appointment

contact us

We’d love to hear from you!

6 + 11 =